Immuneering (IMRX) Projected to Release Quarterly Earnings on Wednesday

Immuneering (NASDAQ:IMRX) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 PM ET.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06). On average, analysts expect Immuneering to post ($1.15) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.

Immuneering Stock Up 5.4%

Immuneering stock opened at $3.68 on Wednesday. Immuneering has a 52-week low of $3.38 and a 52-week high of $8.48. The firm has a market capitalization of $238.32 million, a price-to-earnings ratio of -3.57 and a beta of 0.49. The firm has a 50-day moving average price of $4.22 and a two-hundred day moving average price of $4.79.

Key Immuneering News

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating, and Wall Street analysts collectively rate IMRX “Moderate Buy.” Immuneering Stock Rated Moderate Buy by Wall Street Analysts
• Negative Sentiment: HC Wainwright cut its loss-per-share forecasts across several periods. It lowered its Q4 2026 estimate to a loss of $0.39 from $0.32, and its fiscal 2026 estimate to a loss of $1.24 from $1.10. Forecast losses also increased for fiscal 2027–2030, including estimates of $1.78, $1.87, $1.86 and $0.81 per share, respectively. The more pessimistic outlook on future earnings could weigh on investor sentiment. Immuneering Corporation stock information

Wall Street Analyst Weigh In

IMRX has been the topic of a number of recent analyst reports. Mizuho set a $11.00 price target on Immuneering in a report on Thursday, October 29th. Needham & Company LLC boosted their price objective on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald started coverage on Immuneering in a report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price objective for the company. Chardan Capital upgraded Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.